Ranjan Pai
Partner @ Aarin Capital
Bangalore, India
Ranjan Pai is a Series A investor at Aarin Capital in Bangalore focused on Education and Health Care. Ranjan is a Co-Founder of Aarin Capital. Ranjan, in his own right, is a successful entrepreneur who established Manipal Education and Medical Group (MEMG) with a view to building world-class businesses in Healthcare, Life Sciences and Education & Education Services.He incubated Manipal Global Education Services, a leading global education andeducation services company headquartered in Bangalore, India. The company addresses the entire learning life cycle, covering both on-campus and campus-independent graduate and post-graduate studies, vocational skill development, corporate training and systemic services. Ranjan conceptualized the transformation of Manipal Hospitals into a leading for-profit multi-specialty healthcare chain in India. He set up Stempeutics to undertake cutting-edge research in stem cell therapies. These companies are run by professional management teams and have been funded in part by marquee strategic and financial investors.Ranjan has incubated or has been an active financial investor in several start-ups. His investment track record includes several exceptional exits. Co-founding Aarin Capital is another step in realizing his ambition to actively engage with new ideas and dynamic entrepreneurs in life sciences, health care and training/skill augmentation.A medical doctor by qualification, Ranjan graduated from Kasturba Medical College, Manipal and proceeded to study Hospital Administration in the United States.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 45%
Last updated:
For AI agents: llms.txt
Industries Ranjan Pai invests in
Stages Ranjan Pai invests in
Countries Ranjan Pai invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $707k–$2.1M
- Series A
- $3M–$50M
Investment Focus
Industry
- Education 2 (18%)
- Health Care 2 (18%)
- Information Technology 2 (18%)
- Apps 1 (9%)
- Hotel 1 (9%)
Stage
- Series A 4 (36%)
- Seed 2 (18%)
- Funding Round 2 (18%)
- Secondary Market 1 (9%)
- Venture - Series Unknown 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
TripFactory
|
TripFactory is the Largest Online Holiday Store offering the largest selection of Holidays. We believe great consumer experiences can be delivered by providing expert knowledge and best prices while planning a holiday and we are trying to constantly ensure we deliver, the perfect holiday for our customers. | $50M / Series A / Oct 29, 2024 | |
Brij Hotels
|
Brij is a group of unique hotels that provide joyful hyperlocal experiences. | $4M / Series A / Mar 19, 2024 | |
Aakash Educational Services
|
Aakash Educational Services provide quality coaching & guidance for Engineering Entrance Examination (i.e. JEE Main & Advanced). It is a premier educational institution providing comprehensive test preparatory services for medical, engineering, school/board exams, and competitive scholarship exams through its 201+ Centres branchedacross the country. | $300.1M / Jan 25, 2024 | |
Purplle
|
Purplle is an online store selling cosmetics, fragrances, skin, and hair care products. It gives an online space to beauty and wellness needs that showcases some of the beauty brands and products. Purplle aims to take shopping experience to a different level. Purplle was founded in 2011 and is headquartered in Mumbai, Maharashtra, India. | Secondary Market / Oct 04, 2023 | |
Kites Senior Care
|
KITES is the geriatrics & senior care specialist brand that focuses on Preventive & Primary healthcare needs of its community elders. | $2.1M / Seed / Jan 12, 2023 | |
Rein Games
|
Rein Games is an audience of across mobile,social and online platforms. they are energetic about our games and as anyone might expect are exceptionally stubborn about what comprises great diversion plan and client encounter. they never modest far from attempting new and radical stuff however they adjust their forceful inventive soul with estimationthat unavoidably lowers us, instructs us and dependably enhances their capacity to convey a magnificent playing background. | $706.8K / Seed / Dec 11, 2019 | |
Verloop.io
|
Verloop develops AI software for customer support automation. Its platform provides AI voice agents, chatbots, agent assistance, quality monitoring, analytics, and omnichannel customer engagement for businesses across multiple industries. | $3M / Series A / Nov 26, 2018 | |
InCred
|
InCred is a financial services platform that leverages technology and data-science to make lending quick and easy. It uses technology and data-science to make lending quick, simple and hassle-free. InCred offers a broad portfolio of products that cuts across affordable home loans, personal loans, education loans and SME business loans. | $75M / Venture - Series Unknown / Aug 24, 2016 | |
|
TripFactory
|
TripFactory is the Largest Online Holiday Store offering the largest selection of Holidays. We believe great consumer experiences can be delivered by providing expert knowledge and best prices while planning a holiday and we are trying to constantly ensure we deliver, the perfect holiday for our customers. | $10M / Series A / Jul 31, 2015 | |
Vyome Therapeutics
|
Vyome Biosciences is an innovation driven company, with a vision to develop novel drugs for antibiotics-resistant acne and other opportunist pathogens through a unique pipeline of antibiotics that retard resistance development. Vyome Biosciences’ management team members are the leaders in the field, with deep expertise, demonstratedcapability and a proven track record of successfully launching over 50 products in dermatology & other life sciences areas, and building visionary companies. Vyome’s development platform is completely risk mitigated. Vyome has a deep pipeline of IP based products targeting multiple indications. The *lead molecule (VB 1953)*, which targets the huge unmet need in the drug resistant acne prescription market, will be entering the clinical phase with *USFDA IND Application Filing in Q4 2015*. Vyome has state-of-the-art infrastructure facilities to carry out all its research and lab development work, with full-fledged formulation, analytical, chemistry, biology & molecular biology, clinical and the regulatory divisions. The infrastructure and the team enables Vyome to conceive ideas, develop them and commercialize them at a rapid pace. | $3.3M / Series A / Sep 12, 2012 | |
| See all 11 investments → | |||
Co-Investors
About Aarin Capital
We seek to create long-term value by partnering with talented, hungry management teams actively complementing their skills with our collaborative engagement. We aim to build profitable companies with sustainable value propositions. We appreciate audacious ideas that embed disruptive, customer-focused technologies with the potential to address andtransform large markets.We support our investee companies in generating profitable revenue growth, instituting strong compliance and governance processes, margin enhancement and active operational and strategic management.We dislike financial engineering as a means to demonstrating value creation.We encourage our investee companies to focus on maximising free cash flows by focusing on their core strengths.We are not merely financial investors but also trusted operating partners of our investee companies. Accordingly, we have separate investment and operating teams comprising seasoned, high-quality professionals with a wealth of hands-on operating and investing experience to streamline and maximise the impact and support we can provide to our investee companies.
Aarin Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Mohandas Pai
Co-Founder and Chairman
|
|||
|
Ranjan Pai
Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Ranjan Pai invest in?
Ranjan Pai invests primarily in Education, Health Care and Information Technology startups, most often at Series A and Seed stage. Most of the 11 investments tracked by Shizune back companies in India. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Ranjan Pai's check size?
Ranjan Pai typically joins rounds of $707k–$2.1M at Seed and $3M–$50M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Ranjan Pai participates in.
How do I contact Ranjan Pai?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Ranjan Pai last invest?
The most recent investment recorded for Ranjan Pai closed in Oct 2024. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
